143 related articles for article (PubMed ID: 17673305)
1. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.
Martinez-Cajas JL; Wainberg MA
Antiviral Res; 2007 Dec; 76(3):203-21. PubMed ID: 17673305
[TBL] [Abstract][Full Text] [Related]
2. Resistance to protease inhibitors.
Kuritzkes DR
J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
[TBL] [Abstract][Full Text] [Related]
3. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
4. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.
Wensing AM; van Maarseveen NM; Nijhuis M
Antiviral Res; 2010 Jan; 85(1):59-74. PubMed ID: 19853627
[TBL] [Abstract][Full Text] [Related]
5. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
Youle M
J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
[TBL] [Abstract][Full Text] [Related]
6. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
7. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.
Morand-Joubert L; Charpentier C; Poizat G; Chêne G; Dam E; Raguin G; Taburet AM; Girard PM; Hance AJ; Clavel F
Antivir Ther; 2006; 11(2):143-54. PubMed ID: 16640095
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
Adekale MA; Cane PA; McCrae MA
J Med Virol; 2005 Feb; 75(2):195-201. PubMed ID: 15602725
[TBL] [Abstract][Full Text] [Related]
9. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
Raghavan S; Lu Z; Beeson T; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Gabryelski L; Emini E; Tata JR
Bioorg Med Chem Lett; 2007 Oct; 17(19):5432-6. PubMed ID: 17692518
[TBL] [Abstract][Full Text] [Related]
11. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
13. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.
Bessong PO
Trop Med Int Health; 2008 Feb; 13(2):144-51. PubMed ID: 18304259
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.
Sévigny G; Stranix B; Tian B; Dubois A; Sauvé G; Petropoulos C; Lie Y; Hellmann N; Conway B; Yelle J
Antiviral Res; 2006 Jun; 70(2):17-20. PubMed ID: 16473417
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitor resistance update: where are we now?
Kim R; Baxter JD
AIDS Patient Care STDS; 2008 Apr; 22(4):267-77. PubMed ID: 18422460
[TBL] [Abstract][Full Text] [Related]
17. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
Hoffmann D; Buchberger B; Nemetz C
J Clin Virol; 2005 Apr; 32(4):294-9. PubMed ID: 15780808
[TBL] [Abstract][Full Text] [Related]
18. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
19. A hierarchical model of HIV-1 protease drug resistance.
Goodsell DS
Appl Bioinformatics; 2002; 1(1):3-12. PubMed ID: 15130852
[TBL] [Abstract][Full Text] [Related]
20. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
